Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.55 |
| ▸ | PTAFR | P25105 | 1/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10894210 | 1.00 | ADRA1D (0.55) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL8435468 | 1.00 | ADRA1D (0.55) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL10824976 | 1.00 | ADRA1D (0.55) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| Triacetin SCHEMBL17821531 | 0.97 | PRKCA (0.55) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL13449715 | 0.93 | ALDH1A1 (0.53) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| Triacetin SCHEMBL3680247 | 0.92 | ALDH1A1 (0.57) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| Triacetin SCHEMBL8664971 | 0.91 | PRKCA (0.63) | PRKCAALDH1A1LMNA | |
| SCHEMBL1506792 | 0.91 | PRKCA (0.61) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL1506794 | 0.91 | PRKCA (0.61) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL5017334 | 0.89 | PRKCA (0.47) | ADRA1DPTAFRHTR1DHTR2CADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370516-B2 | Bio based plasticizer with improved properties and processing characteristics of polymer | FINE ORGANICS INDUSTRIES PVT LTD. (IN) | 2019-08-06 | — | — | US | disclosed |
| US-20180037719-A1 | A BIO BASED PLASTICIZER WITH IMPROVED PROPERTIES AND PROCESSING CHARACTERISTICS OF POLYMER | FINE ORGANICS INDUSTRIES PVT LTD. (IN) | 2018-02-08 | — | — | US | disclosed |
| EP-0679337-B1 | Cheese coating composition and method for producing protective coatings on cheese | DANISCO (DK) | 1999-12-22 | — | — | EP | disclosed |
| US-5516536-A | ACETIC ESTERS OF LONG CHAIN FATTY ACID MONOGLYCERIDES | DANISCO A/S (DK) | 1996-05-14 | — | — | US | disclosed |
| EP-0679337-A2 | Cheese coating composition and method for producing protective coatings on cheese | DANISCO A/S (DK) | 1995-11-02 | — | — | EP | disclosed |
| WO-1992001386-A1 | REDUCED CALORIE CONFECTIONERY COMPOSITIONS | NABISCO, INC. (US) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037719-A1 | A BIO BASED PLASTICIZER WITH IMPROVED PROPERTIES AND PROCESSING CHARACTERISTICS OF POLYMER | PHOSPHO1, ABHD5, AGPAT5 | ADRA1D 1073/4885PTAFR 2543/4885HTR1D 2078/4885 |
| US-10370516-B2 | Bio based plasticizer with improved properties and processing characteristics of polymer | ABHD5, PHOSPHO1, AGPAT5 | ADRA1D 1293/4885PTAFR 2534/4885HTR1D 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.